CCL22/MDC Antibody (57226) [Alexa Fluor® 488]

• Applications: WB, B/N, ELISA(Cap), ELISA(Det)
• Clone: 57226
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 488

CCL22/MDC Antibody (57226) [Alexa Fluor® 488] Summary

• Immunogen: E. coli-derived recombinant human CCL22/MDC
  Gly25-Gln93
  Accession # O00626.1
• Specificity: Detects human CCL22/MDC in ELISAs and Western blots. In ELISAs, no cross-reactivity with recombinant mouse CCL17, recombinant human (rh) CCL17, or rhCCL21 is observed.
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Background

CCL22, also named stimulated T cell chemotactic protein (STCP-1) and MDC, is a CC chemokine initially isolated from clones of monocyte-derived macrophages. Human CCL22 cDNA encodes a precursor protein of 93 amino acid residues with a 24 amino acid residue predicted signal peptide that is cleaved to yield a 69 amino acid residue mature 8 kDa protein. At the amino acid sequence level, CCL22 shows less than 35% identity to other CC chemokine family members. Human CCL22 is expressed in dendritic cells, macrophages and activated monocytes. In addition, CCL22 expression is also detected in the tissues of thymus, lymph node and appendix. The gene for human CCL22 has been mapped to chromosome 16 rather than chromosome 17 where the genes for many human CC chemokines are clustered. Recombinant or chemically synthesized mature CCL22 has been shown to induce chemotaxis or Ca²⁺ mobilization in dendritic cells, IL-2 activated NK cells, and activated T lymphocytes. A CD8⁺ T lymphocyte-derived secreted soluble activity that suppresses infection by primary non-syncytium-inducing and syncytium-inducing HIV-1 isolates and the T cell line-adapted isolate HIV-1_IIIB, has been identified as CCL22. Based on amino-terminal sequence analysis, the major CD8⁺ T lymphocyte-derived CCL22 protein yielded an amino-terminal sequence of YGANM, which is two amino acid residues shorter than the predicted mature CCL22. The difference in potency between the two mature CCL22 isoforms has not been determined.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.